“`html
Relmada Therapeutics Unveils NDV-01 for High-Risk Bladder Cancer at AUA2025
Relmada Therapeutics presented an abstract on NDV-01 for high-risk NMIBC at the AUA2025 conference.
Overview of NDV-01’s Presentation
Relmada Therapeutics, Inc. announced an important presentation at the American Urology Association (AUA2025) conference in Las Vegas. The study focuses on NDV-01, an investigational therapy that combines gemcitabine and docetaxel for high-risk non-muscle invasive bladder cancer (NMIBC). This abstract will be presented on April 28, 2025. NDV-01 is engineered for intravesical use, facilitating sustained drug release which aims to enhance efficacy, reduce side effects, and improve patient adherence. The therapy is intended as a first-line option for high-grade NMIBC and may benefit patients who have not found relief with previous treatments. Relmada remains committed to innovative therapy development, also working on programs like sepranolone for compulsion-related disorders. The current NMIBC treatment market represents a substantial opportunity due to high recurrence rates and limited therapeutic options.
Positive Aspects of NDV-01
- The abstract presentation at the AUA2025 spotlights Relmada’s dedication to enhancing bladder cancer treatment options.
- NDV-01 introduces a potentially first-line therapy for high-risk non-muscle invasive bladder cancer, showcasing innovation in drug formulation intended to improve patient outcomes.
- Its unique sustained-release mechanism may elevate overall efficacy while minimizing systemic toxicity, positioning it as a compelling option amid high recurrence rates in available treatments.
- The U.S. NMIBC market is projected to be multi-billion dollar, indicating significant commercial potential for Relmada’s investigational therapies, especially as current treatments like BCG face limitations.
Challenges Facing NDV-01
- There are inherent risks and uncertainties linked to the Phase 2 clinical trials for NDV-01, including the possibility that top-line results may not fully reflect trial outcomes or that subsequent studies may fail to deliver expected results.
- The high recurrence rate for NMIBC is noted, which may raise concerns regarding the long-term efficacy of novel treatments like NDV-01.
- Further studies are implied to confirm efficacy and safety, suggesting current data may not yet inspire widespread confidence in the product’s success.
Frequently Asked Questions
What is NDV-01?
NDV-01 is an investigational sustained-release formulation combining gemcitabine and docetaxel for treating high-risk non-muscle invasive bladder cancer.
When will NDV-01 be presented at AUA2025?
The presentation of NDV-01 is scheduled for April 28, 2025, from 10:04 AM to 10:12 AM PT.
How does NDV-01 enhance treatment for bladder cancer?
NDV-01 improves treatment by maximizing local drug concentrations, extending exposure time, and minimizing systemic toxicity compared to conventional therapies.
What is the significance of NMIBC in bladder cancer cases?
Non-muscle invasive bladder cancer (NMIBC) makes up around 75% of bladder cancer cases and is known for its high recurrence rates.
How does Relmada Therapeutics promote innovation in biotechnology?
Relmada Therapeutics focuses on developing innovative therapies that provide significant clinical advantages for targeted patient populations, such as NDV-01 for NMIBC.
$RLMD Hedge Fund Activity
In the latest quarter, 14 institutional investors increased their stakes in $RLMD, while 43 reduced their positions. Notable changes include:
- DEEP TRACK CAPITAL, LP divested 674,833 shares (-100.0%), amounting to an estimated $350,913.
- MILLENNIUM MANAGEMENT LLC sold off 561,826 shares (-100.0%), valued at approximately $292,149.
- VESTAL POINT CAPITAL, LP reduced 490,000 shares (-100.0%), realizing about $254,800.
- OPALEYE MANAGEMENT INC. eliminated 480,000 shares (-100.0%) for an estimated $249,600.
- JPMORGAN CHASE & CO decreased 277,359 shares (-88.0%), worth around $144,226.
- PALO ALTO INVESTORS LP cut 237,254 shares (-32.4%), representing an estimated $123,372.
- SHAY CAPITAL LLC reduced their holdings by 175,547 shares (-100.0%), which is valued at approximately $91,284.
Abstract Overview
Abstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained Release Gemcitabine Docetaxel Combination (NDV-01) in High Risk NMIBC
Session: Clinical Trials in Progress: Bladder Cancer
Location: Hall C, The Square, Learning Lab
Presentation Date: April 28, 2025
Presentation Time: 10:04 AM PT to 10:12 AM PT
About NDV-01
NDV-01 is an innovative sustained-release formulation of two well-established chemotherapy agents, gemcitabine and docetaxel. It is designed for intravesical delivery and is prepared for in-office use without the need for anesthesia or specialized equipment. NDV-01 forms a spherical soft matrix in the bladder that sequesters drugs and releases them gradually as the matrix dissolves over time.
“`
NDV-01: A Potential Game Changer for Non-Muscle Invasive Bladder Cancer
NDV-01 is designed to deliver a steady release of gemcitabine and docetaxel over a 10-day period through instillations. This approach aims to enhance efficacy, minimize side effects, and improve dosing frequency, potentially leading to better patient compliance and outcomes. The treatment may serve as a first-line therapy for high-grade non-muscle invasive bladder cancer (HG-NMIBC) and further cater to patients who have not succeeded with other therapies, including Bacillus Calmette-Guérin (BCG) immunotherapy. Additionally, there’s potential to expand its use to other non-muscle invasive bladder cancer subtypes, including intermediate-grade cases.
The intellectual property for NDV-01 is backed by several patents extending until 2038.
Understanding Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder cancer accounts for over 90% of approximately 83,000 new urothelial cancer cases in the U.S. The 5-year survival rates for bladder cancer patients range from 70% to 96%, dropping to only 6% for those with advanced disease. Approximately 75% of bladder cancer cases are classified as non-muscle invasive (NMIBC), with around 50% of these being high-grade, indicating a heightened risk of progression and recurrence. Research shows that NMIBC has a recurrence rate of 50-75% over seven years, with an estimated 600,000 patients in the U.S. suffering from this condition.
The NMIBC market in the U.S. represents a multi-billion dollar opportunity. Global projections indicate even higher growth due to the rising incidence of bladder cancer and the increasing need for effective, minimally invasive therapies like NDV-01. Current approved treatments are limited, primarily relying on BCG immunotherapy, which has been supply constrained recently. High recurrence rates necessitate frequent re-treatment, creating a demand for alternatives. Other emerging therapies include immunotherapy combinations, single-agent chemotherapy formulations, and targeted therapies. NDV-01 stands apart due to substantial published data supporting the efficacy of gemcitabine and docetaxel, its ease of administration, and the potential for sustained effectiveness. Moreover, broadening its application to salvage treatment or other subgroups in NMIBC may further enhance its market potential.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology firm focused on developing innovative therapies aimed at delivering significant benefits to specific patient groups.
The lead investigational program, NDV-01, for HG-NMIBC is currently undergoing a Phase 2 study. Preparations are also in progress to advance sepranolone, a Phase 2b candidate for disorders related to compulsion such as Tourette’s Syndrome and Prader-Willi Syndrome, into further trials.
Forward-Looking Statements:
In accordance with the Private Securities Litigation Reform Act of 1995, the following contains forward-looking statements as defined by law. This press release includes anticipatory statements regarding NDV-01’s Phase 2 study outcomes and potential future development. These statements are based on the management’s current expectations and beliefs but are inherently subject to a variety of risks and uncertainties. Several factors may cause actual outcomes to diverge significantly, including, but not limited to, the impact of Phase 2 data presentations at forthcoming medical conferences, the possibility of positive Phase 2 results, and other risks outlined in the Company’s SEC filings. Forward-looking statements are not guarantees, and actual outcomes may vary widely. Relmada does not have an obligation to update these statements based on new information or future developments.
Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]
Media Inquiries:
Corporate Communications
[email protected]
